Back to the program

Contributed Papers

Innovative Methods in Oncology Clinical Trials

Wed, Aug 7, 10:30 AM - 12:20 PM

Jing ZhangChair

Biopharmaceutical Section

7 Presentations

An evaluation of machine learning method to estimate propensity score in treatment switching

10:35 AM - 10:50 AM

Yuichiro Kaneko (Astellas Pharma)

Co-authors: Musashi Fukuda

Assessing Survival Benefits of Immunotherapy Using Long-Term Average Hazard

10:50 AM - 11:05 AM

Miki Horiguchi (Dana-Farber Cancer Institute)

Co-authors: Hajime Uno (Dana-Farber Cancer Institute)

Comparing Group Sequential Design Methods for Immunotherapy Trials for Renal Cell Carcinoma Patients

11:05 AM - 11:20 AM

Yuanyuan Han (Bristol Myers Squibb)

Co-authors: Yimei Li, Jianrong Wu (University of New Mexico, Dept. of Internal Medicine)

Hierarchical Models to Improve Estimating Biomarker Utility in Early Multi-cohort Oncology Trials

11:20 AM - 11:35 AM

Jared Lunceford (Merck & Co., Inc.)

Co-authors: Lixin Lang (Merck & Co., Inc.), Mackenzie Edmondson, Devan Mehrotra (Merck & Co., Inc.)

Improving Safety Evaluations for Oncology Compounds

11:35 AM - 11:50 AM

Ellen Snyder (Merck & Co., Inc.)

Co-authors: Wei Wang (Merck & Co., Inc.)

Optimizing Oncology Trials: Roadmap of Statistical Methodology for Seamless Phase 2/3 Designs

11:50 AM - 12:05 PM

Co-authors: Philip He (Daiichi Sankyo Inc.), Deepak Nag Ayyala (Takeda Pharmaceuticals), Haiming Zhou (Daiichi Sankyo, Inc.)

PROvision – Insights into Submitting Patient-Reported Outcome Data in Cancer Clinical Trials

12:05 PM - 12:20 PM

Ting Yu Chen (US FDA)

Co-authors: Mallorie Fiero (FDA), Flora Mulkey (FDA)

↑